Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Cholesterol drug gets European approval

  • Comment
A new combination treatment for high cholesterol has been approved for marketing in the European Union.

Nicotinic acid/laropiprant (Tredaptive) 1,000mg/20mg modified-release
Tablets is a new lipid-modifying therapy for patients with dyslipidaemia and primary
Hypercholesterolaemia.

Its manufacturer, Merck Sharp and Dohme, said it had been shown in trials to reduce LDL-cholesterol and triglycerides, while increasing HDL-cholesterol levels.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.